/ Not yet recruitingPhase 2IIT AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option.
/ Not yet recruitingNot Applicable Evaluation Study of a New Management Strategy for Gastroesophageal Reflux Disease (GERD) - GMP
/ Not yet recruitingPhase 3 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib with Lomustine to the Efficacy of Lomustine Alone - REGAL
100 Clinical Results associated with Astrazeneca Plc /Anti Infective Business/
0 Patents (Medical) associated with Astrazeneca Plc /Anti Infective Business/
100 Deals associated with Astrazeneca Plc /Anti Infective Business/
100 Translational Medicine associated with Astrazeneca Plc /Anti Infective Business/